Delivery Order SPE2DB22D2206-SPE2DB25FFJ97

Award Date 1/31/25
Potential Completion Date 2/24/25
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $178,310.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 10 MG CAPSULE 100S, a medical product, with an ultimate completion date of February 4, 2025. The contract is a Firm Fixed Price arrangement and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite...
This federal contract award is a delivery order with a ceiling value of $24,963.40 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a period of performance through November 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,963.40, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 5 MG CAPSULE 28S. The contract has an ultimate completion date of January 22, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,890.20, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of January 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm-fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $99,853.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,566,756,379 units of the medication REVLIMID 10 MG CAPSULE 28S. The award does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) and is valued at $49,926.80. The contract is a Firm Fixed Price Delivery Order that runs through February 18, 2025. The award is not associated with a set-aside program, indicating open competition. The contract covers the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product, to support DLA's medical supply needs. Amerisourcebergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a delivery order for the supply of 10 mg Revlimid capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of December 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
The federal contract award SPE2DB22D3501|SPE2DB25FUD64 was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm fixed-price delivery order is for the supply of 4566957013 - REVLIMID 25 MG CAPSULE 21S. This contract award is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $267,465.18 firm fixed-price delivery order is for the provision of REVLIMID 10 MG CAPSULE 100S, a pharmaceutical product, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The award is associated with a larger Indefinite Delivery Contract (IDC) held by...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FFJ97
    Delivery Order

This federal contract award, valued at $24,963.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The specific award is for the supply of REVLIMID 2.5 MG CAPSULE 28S, a pharmaceutical product, with a completion date of February 24, 2025. This contract award did not have a set-aside designation, indicating open competition.

Generated 5/4/25, 1:04 AM